



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 201 236 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)
INID code(s) 71

(51) Int Cl.7: **A61K 31/135**, A61P 31/12,
A61P 31/16, A61P 31/22,
A61P 31/14

(48) Corrigendum issued on:
09.10.2002 Bulletin 2002/41

(86) International application number:
PCT/JP00/04286

(43) Date of publication:
02.05.2002 Bulletin 2002/18

(87) International publication number:
WO 01/001978 (11.01.2001 Gazette 2001/02)

(21) Application number: **00940873.3**

(22) Date of filing: **28.06.2000**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

• **Matsumori, Akira**
Minoh-shi, Osaka 562-0045 (JP)

(72) Inventor: **MATSUMORI, Akira**
Minoh-shi, Osaka 562-0045 (JP)

(30) Priority: **30.06.1999 JP 18529799**

(74) Representative:
von Kreisler, Alek, Dipl.-Chem. et al
Patentanwälte
von Kreisler-Selting-Werner
Postfach 10 22 41
50462 Köln (DE)

(71) Applicants:
• **Mitsubishi Pharma Corporation**
Osaka-shi, Osaka 541-0046 (JP)

(54) **MEDICINAL COMPOSITIONS FOR PREVENTING OR TREATING VIRAL MYOCARDITIS**

(57) The present invention aims at providing a pharmaceutical composition for the prophylaxis or treatment, irrespective of the kind of virus, of viral myocarditis or viral diseases induced by viral myocarditis, by the treatment or prevention of the onset of cytotoxicity in various organs, and a method of the prophylaxis or treatment. The present invention also relates to a pharmaceutical composition for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis,

which contains 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof as an active ingredient. The present invention further relates to a method for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which includes administering an effective amount of the aforementioned compound or a pharmacologically acceptable salt thereof.

EP 1 201 236 A8